Reports
Publications
Presented papers
- Poster at European Biotechnology Congress, October 3rd – 5th 2024| Istanbul, Turcia. The relevance of cannabinoid receptor ligands in Alzheimer’s disease management by Gabriela Dumitrita Stanciu; B.I. Tamba; D.C. Ababei.
- Poster at ECNP Congress, 21-24 September 2024| Milan, Italy. Therapeutic implications of cannabinoids with enhanced binding affinity for targeting the expanded endocannabinoid system in Alzheimer’s disease management by Gabriela Dumitrita Stanciu; B.I. Tamba.
- Poster at ESLAV-ECLAM2023 Annual Meeting, 26-27 June 2023| Tallinn, Estonia. Neuroprotective effect of sodium glucose cotransporter 2 inhibitors for dementia due to Alzheimer’s disease by Gabriela Dumitrita Stanciu, D.C. Ababei, C. Solcan, V. Bild, B.I. Tamba.
- Oral presentation at 1st Central-East European Laboratory Animal Science Congress – CELASC Congress, May 30- June 1, 2023| Praga, Cehia. Advanced Research and Development Center for Experimental Medicine: ”Prof. Ostin C. Mungiu” – Infinite Solutions, by Gabriela Dumitrita Stanciu.
- Poster at 1st Central-East European Laboratory Animal Science Congress – CELASC Congress, May 30- June 1, 2023| Praga, Cehia. Selective cannabinoid receptor type 2 and donepezil combined therapy in Alzheimer’s disease – preliminary data by Gabriela Dumitrita Stanciu, B.I. Tamba.
- Poster at 5th Global Conference on Neuroscience and Neurological Disorders, November 03-04, 2022| Berlin, Germany. Targeting CB2 receptors: potential investigational therapies for dementia due to Alzheimer’s disease by Gabriela Dumitrita Stanciu, B.I. Tamba.
- Poster at 6th Edition of International Conference on Neurology and Brain Disorders during October 24-26, 2022| Orlando, Florida, USA. Preclinical in vivo study on selective cannabinoid receptor type 2 and donepezil combined therapy in Alzheimer’s disease by Gabriela Dumitrita Stanciu, B.I. Tamba.
Published papers
- Article: Stanciu GD; Ababei CD; Solcan C; Uritu CM; Crăciun VC; Pricope CV; Szilagyi A; Tamba BI. Exploring cannabinoids with enhanced binding affinity for targeting the expanded endocannabinoid system: a promising therapeutic strategy for Alzheimer’s disease treatment. Pharmaceuticals. 2024; 17, 530.
- Article: Stanciu GD; Ababei DC; Solcan C; Bild V; Ciobica A; Beschea Chiriac S-I; Ciobanu LM; Tamba B-I. Preclinical studies of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, and donepezil combined therapy in Alzheimer’s disease. Pharmaceuticals. 2023; 16, 1620.
- Review paper: Stanciu GD; Ababei DC; Rusu RN; Bild V; Tamba BI. Exploring the involvement of the amyloid precursor protein A673T mutation against amyloid pathology and Alzheimer’s disease in relation to therapeutic editing tools. Pharmaceutics. 2022; 14(6): 1270.
Courses
- Summer school of ESLAV-ECLAM ”Diseases and diagnostics of animals used in science”, 28-30 June 2023, Tallinn, Estonia.
- From behavioral methods for assessing cognitive performance to neurodegeneration – relevant solutions for improving preclinical to clinical translation in Alzheimer’s disease research by Gabriela Dumitrita STANCIU at Advanced Research and Development Center for Experimental Medicine “Prof. Ostin C. Mungiu” – CEMEX, Iasi, Romania during the 18th edition of the International Congress for medical Students and Young Doctors – CONGRESSIS, 3rd-7th of May, 2023.
- Cognitive and behavioral assessment in dementia due to Alzheimer’s disease on laboratory animals by Gabriela Dumitrita STANCIU at Advanced Research and Development Center for Experimental Medicine “Prof. Ostin C. Mungiu” – CEMEX, Iasi, Romania during the 17th edition of the International Congress for medical Students and Young Doctors – CONGRESSIS, 11th- 15th of May 2022.
Books
- Stanciu GD, Coman C, Moroșan SZ – Îndrumător de medicină experimentală modele animale și metode de testare în proceduri preclinice in vivo, Ed. “Gr. T. Popa”, Iași, 2024. ISBN: 978-606-544-965-7.